Neomycin (Neo-Fradin, Mycifradin)
Other Medications
Description
Neomycin is an aminoglycoside antibiotic used as supportive care in colorectal cancer treatment, primarily for bowel decontamination before surgical procedures. It is administered orally as part of mechanical bowel preparation protocols to reduce intestinal bacterial load and decrease the risk of surgical site infections following colorectal surgery. Neomycin may also be used in research settings to modify gut microbiota composition prior to interventions like fecal microbiota transplantation in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer.
Mechanism of Action
Neomycin binds irreversibly to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing bacterial cell death. When administered orally, it acts locally within the gastrointestinal tract with minimal systemic absorption, selectively reducing gram-negative aerobic bacteria in the colon.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Neo-Fradin, Mycifradin |
| Category | Other Medications |
 Status | FDA Approved |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.